Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)

Inclusion Criteria: * Histologic evidence of HCC, Barcelona-Clinic Liver Cancer (BCLC) stage B * FFPE (Fixed-paraffin Embedded) tumor tissue (two cores preferred) for biomarker analysis * Prior radioembolization, local ablative therapies (radiofrequency, microwave or cryoablation), radiation (external beam or stereotactic), or hepatic resection permitted if completed ≥ 4 weeks prior to study enrollment and if patient has recovered with ≤ grade 1 toxicity and if untreated measurable disease is present. * Radiographically measurable disease by mRECIST in at least one site not previously treated by local therapies. * Must not be receiving treatment with other investigational agents and must not have received any other investigational agent's ≤ 4 weeks prior to registration. * Age ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Required lab and acceptable range criteria. * Women of child-bearing potential and men must agree to use 2 methods of adequate contraception. * No contraindications to TACE therapy * Child-Pugh Score A-B * Ability to understand and the willingness to sign a written informed consent, and the willingness to comply with the requirements of the protocol. * Life expectancy greater than 3 months. * Adequate baseline organ and marrow function Exclusion Criteria: * History of hepatitis B * Women must not be pregnant or breastfeeding * Presence of other malignancies * Active or history of Tuberculosis * Patients with known HIV positive status * Conditions with impaired immunity or on immunosuppressive medications such as oral steroids, calcineurin inhibitors, or anti-proliferative agents. * Must have no evidence of significant, uncontrolled concomitant diseases * Must have no ongoing or active, uncontrolled infections